PATENTS: COUNTDOWN, page-16

ASX Announcement and Media Release
Date: 5 September 2002
___________________________________________________________________________________

PEPTECH US ANTI-TNF PATENT ISSUED

Peptech today announced that it has received official confirmation from the US Patent and Trademark Office that patent application number 9/737,121 will be issued on 10 September 2002 under patent number 6,448,380 entitled “Tumour Necrosis Factor Antibodies”.

Peptech is already receiving royalties from sales of Remicade in Australia, Canada, France, Germany, Italy, Switzerland and the United Kingdom. The next significant milestone is the receipt of the royalties from sales of this anti TNF antibody product in the US. Issuance of this patent significantly enhances our TNF antibody patent family and will aid in the achievement of the above milestone.


About Peptech Limited

Peptech Limited is an Australian biopharmaceutical company, focussed on the development and commercialisation of human therapeutic proteins. Peptech’s portfolio of patents covering the use of antibodies and/or antibody fragments that bind to TNF, has been licensed to Centocor, Inc. (a subsidiary of Johnson and Johnson) and Knoll AG (now part of Abbott Laboratories). Under these license agreements, Peptech is to receive ongoing royalties on sales of their products, Remicade and D2E7, respectively, in countries in which a valid patent has been issued. European and US marketing approval for D2E7 is expected in 2003.